Elevated Lp-PLA2 levels are associated with an increased risk of development of a coronary heart disease (CHD). We are happy to inform you that we are soon able to provide antibodies for lipoprotein-associated phospholipase A2 (Lp-PLA2/PLAC), recombinant antigen and pair recommendations.

Antibodies have been tested using patient samples and their performance correlates well with the established ELISA-tests. Antibodies will allow development of sandwich-type assays with high sensitivity and good linearity. The antibodies are available in bulk scale.

The antibodies will be available within H1 and should you need further information please do not hesitate to contact us at hytest@hytest.fi